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Abstract
Fibroblast growth factors (FGFs) are recognized targets for the development of therapies against angiogenesis-driven
diseases, including cancer. The formation of a ternary complex with the transmembrane tyrosine kinase receptors (FGFRs),
and heparan sulphate proteoglycans (HSPGs) is required for FGF2 pro-angiogenic activity. Here by using a combination of
techniques including Nuclear Magnetic Resonance, Molecular Dynamics, Surface Plasmon Resonance and cell-based binding
assays we clarify the molecular mechanism of inhibition of an angiostatic small molecule, sm27, mimicking the endogenous
inhibitor of angiogenesis, thrombospondin-1. NMR and MD data demonstrate that sm27 engages the heparin-binding site
of FGF2 and induces long-range dynamics perturbations along FGF2/FGFR1 interface regions. The functional consequence
of the inhibitor binding is an impaired FGF2 interaction with both its receptors, as demonstrated by SPR and cell-based
binding assays. We propose that sm27 antiangiogenic activity is based on a twofold–direct and allosteric–mechanism,
inhibiting FGF2 binding to both its receptors.
Citation: Pagano K, Torella R, Foglieni C, Bugatti A, Tomaselli S, et al. (2012) Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation
by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. PLoS ONE 7(5): e36990. doi:10.1371/journal.pone.0036990
Editor: Paolo Carloni, German Research School for Simulation Science, Germany
Received February 3, 2012; Accepted April 11, 2012; Published May 14, 2012
Copyright:  2012 Pagano et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Fondazione Cariplo (project: 2008.2198), Ministero della Salute (GR2007), Ministero dell’Istruzione dell’Universita ` e della
Ricerca (MIUR) and Associazione Italiana per la Ricerca sul Cancro (AIRC). LR acknowledges Fondazione De Marco for financial support. The funders hadn or o l ei n
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: laura.ragona@ismac.cnr.it (LR); g.colombo@icrm.cnr.it (GC)
Introduction
Fibroblast growth factors (FGFs) and their receptors are
emerging as promising therapeutic targets for a wide array of
pathologies, including angiogenesis-driven diseases. Several hu-
man solid tumors, including breast, bladder, prostate, endometrial
and lung cancers, as well as haematological malignancies, are
associated with deregulated FGF signaling [1]. Aberrant FGF
signalling contributes to the development of cancer by acting on
both cancer and stromal cells, eliciting different cell functions and
biological processes such as angiogenesis and cancer cell prolifer-
ation, survival, invasion and metastasis. FGFs signalling requires
the formation of a ternary complex composed by FGFs, the high
affinity transmembrane tyrosine kinase receptors (FGFR1 through
FGFR4), and heparan sulphate proteoglycans (HSPGs) [2].
Therapeutic strategies, aimed at interfering with the formation
of the complex between FGF and its receptors (either FGFRs or
HSPGs), are being developed and include small molecule
inhibitors of FGFR tyrosine kinase activity, monoclonal antibodies
targeting FGFRs, and a wide array of natural or synthetic
molecules able to sequester FGFs preventing their interaction with
FGFRs and HSPGs [3].
One of the most potent endogenous inhibitors of angiogenesis is
thrombospondin-1 (TSP-1) [4,5]. It binds to FGF2 with an affinity
similar to heparin [6,7], inhibiting the FGF2-mediated angiogenic
activation of endothelial cells. We have recently identified an
antiangiogenic FGF2-binding site in the type III repeats of TSP-1,
and demonstrated that binding of FGF2 to this site inhibits
angiogenesis by sequestration of the growth factor [8]. Then,
peptide array analysis, binding experiments and SPR analysis
guided us to identify a linear amino acidic sequence of type III
repeats of TSP-1 that bound FGF2 in the mM range. Using a
pharmacophore-based approach, three non-peptidic small mole-
cules, retaining the antiangiogenic activity of the entire TSP-1 and
the type III repeats, were identified. The most active molecule,
sm27 (IUPAC name: 4-hydroxy-6-((((8-hydroxy-6-sulfo-2-naph-
thyl) amino)carbonyl)amino)-2-naphthalenesulfonic acid)
(Figure 1A), prevented the binding of FGF2 to endothelial cells,
inhibited FGF2-induced endothelial cell proliferation and FGF2-
induced angiogenesis in the chicken chorioallantoic membrane
assay [9]. Since its stereochemical properties optimally match the
design rules proposed to improve the pharmacological applicabil-
ity of naphthalene sulfonates in antiangiogenesis [10,11], although
with an activity not suitable to make it an immediate drug-
candidate, sm27 can be considered the prototype lead compound
for the ongoing development of potent FGF2-targeting drugs.
The observed antiangiogenic effects of sm27 could be due to a
direct binding of the inhibitor to one of the two distinct binding
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[12,13,14,15,16,17] or through an indirect perturbation of the
conformational properties of the FGF2 sub-structures mostly
involved in complex formation with FGF2 receptors. To clarify the
molecular details underpinning sm27 inhibition mechanisms, we
have set out to characterize the structural properties of the FGF2-
sm27 complex and to investigate the perturbative effects of sm27
on the global FGF2 dynamical properties. To this aim, we have
used a combination of techniques including Nuclear Magnetic
Resonance (NMR) and Molecular Dynamics (MD) simulations.
Surface Plasmon Resonance (SPR) and binding assays on cultured
cells have been exploited to evaluate the effects of sm27 on FGF2
binding to its two distinct classes of receptors and on the formation
of the FGF2/FGFR1/HSPGs ternary complex.
Data discussed herein reveal ligand-dependent modulation of
internal motions, suggesting that the non peptidic TSP-1 mimic
interferes with the formation of FGF2-receptors complex with a
twofold mechanism of action: i) a direct inhibition of FGF2
binding to HSPGs and ii) a long-range modulation of the dynamic
properties of the FGF2 surfaces involved FGFR1 recognition.
Results
Mapping the FGF/sm27 interaction by NMR and docking
simulations
In order to map the sm27-binding site on FGF2, a series of 2D
15N-
1H HSQC experiments were acquired as sm27 was titrated
into a solution of
15N-enriched FGF2 protein. First, a 19 steps
titration was performed from 0:1 to 4:1 sm27:FGF2 ratio. The
titration progress was suggestive of an intermediate to fast
exchange phenomenon, which points to a weak binding. The
chemical shift perturbation (CSP) analysis of the FGF2
1H and
15N
NMR resonances upon addition of sm27 clearly indicated no
global tertiary structure modification of the FGF2 molecule upon
sm27 binding. Residues showing significant CSP are R129 and
K144 (Figure 1B, C), thus clearly identifying the sm27 binding site.
This region, located in the long b10–b12 loop, is part of the
reported heparin binding site [12,15,16,18,19].
1H and
15N
chemical shift deviations were also analyzed separately to finely
describe both effects of direct ligand interaction and local structure
rearrangements correlating with the binding process [20]. The
separate analysis revealed a high variation of R129
15N chemical
shift, which was interpreted as a change of K128 side chain
conformation upon sm27 binding (Figure S1).
CSP of FGF2 resonances upon sm27 interaction were employed
to derive a structural model of the sm27-FGF2 complex through a
data driven docking approach with the software HADDOCK2.0
[21,22]. Ambiguous interaction restraints (AIR) were indeed
defined for residues K128, R129 and K144. In addition four
unambiguous interaction restraints were defined on the basis of the
NOEs observed in the 3D HSQC-NOESY experiment, recorded
on the FGF2:sm27 1:2 sample, .involving R129 and K144 amides
and sm27 H5 or H1
yl and H7 or H3
yl resonances (nomenclature
as in Figure 1A, Table S1, Table S2). A total of 4 unambiguous
and 18 ambiguous interaction restraints were used to drive the
docking process (Table S1). Analysis of the final 200 water-refined
models for the FGF2-sm27 complex resulted in 6 different clusters
of at least 10 structures and the statistics of the first three clusters is
presented in Table S3. All the HADDOCK solutions presented
similar features, with sm27 engaging the heparin binding site.
Cluster 1 is the most populated and has the best average
HADDOCK score and was therefore chosen as representative of
the FGF2-sm27 complex (Table S3). The bundle of the 10 lowest-
energy structures from cluster 1 was selected for further analysis
(Figure 1D). A limited spread within the ensemble was observed, as
deduced from RMSD values from their mean structure, calculated
on residues 25–155, obtained for Ca: 0.5260.12 A ˚ and for non-
hydrogen atoms: 1.4560.35 A ˚. Protein/ligand interactions,
conserved in all the ten models, are depicted on the structure in
Figure 1E. Two ion-pair electrostatic interactions, involve the
cationic side chains of K128 and K144 residues and the anionic
sulphonic moiety of sm27. In addition, hydrophobic interactions
are established between the carbon atoms of sm27 and the
aliphatic branches of K128, R129, Q143, and K144 side chains.
Characterizing the internal dynamics of FGF2 through
NMR
Changes in HSQC peak intensities upon sm27
binding. Peak intensity in HSQC spectra is a sensitive probe of
exchange rates and relaxation rates affecting individual residues.
The changes in the normalized peak intensities as a function of
ligand additions thus provide useful dynamic and conformational
information about the binding event. The peak intensity variations
ofeachFGF2residueongoingfromtheapotoholo(2:1sm27:FGF2
ratio) form is reported in Figure 2A and are summarized on FGF2
structureinFigure2B.ThestrongesteffectswereobservedforR129,
K144 and A145. Interestingly, these residues showed a very low
intensity in the apo-FGF2 HSQC spectrum, probably due to
conformational exchange, and their intensities grew up to the
average value of the molecule, upon sm27 binding. The behavior of
glutamines and asparagine side-chains could be analyzed from the
same HSQC spectra, and significant changes were observed for
residues N36, Q132 and Q143.
T1, T2, and NOE relaxation parameters. Relaxation
parameters, R1, R2, and NOE, were measured for the apo and
thesm27-boundstateofFGF2toassesstheroleofproteindynamics,
in the picoseconds-nanoseconds time-scale, in the recognition
phenomenon.
The comparison of the relaxation parameters obtained for apo
and holo FGF2 (Figure S2) indicated a similar overall pattern in
the two states. The mobile nature of the long N-terminal tail
(residues 3–29) and of the C-terminal tail, suggested by R1, R2
and NOE values is maintained upon sm27 binding. The average
R1, R2, and NOE values, calculated excluding the mobile N-
terminal tail 1–29 are reported in Table S4. In apo-FGF2, five
residues presented R2 values significantly higher than the average
plus two standard deviations, namely E87 and G89 (b6–b7 loop),
N110 (b8–b9 turn), R129 and K144 (b10–b12 loop). These
residues are possibly affected by conformational exchange and/or
solvent exchange processes. Interestingly, upon sm27 binding,
R129 and K144 R2 values decreased, assuming values typical of
the protein core residues, suggesting that the conformational
exchange is quenched by the ligand. As reported above, R129 and
K144 are the two residues showing the highest chemical shift
variation and intensity increase upon sm27 binding, thus defining
a sm27 anchoring region.
Modelfree analysis.
15N R1 and R2 relaxation rates and
steady-state
1H-
15N NOEs were analyzed using the Modelfree
program [23] to obtain values for the residue-by-residue gener-
alized order parameter (S2), which reflects the amplitude of the
fast internal motion of the H
N-N bond vectors in the picoseconds-
nanoseconds time scale. The obtained S2 values are reported in
Figure 2C as a function of the residue number and plotted
accordingly on FGF2 molecule in Figure 2D, E for apo- and holo-
FGF2, respectively. Similar average S2 values, calculated for
residues 30-153, were obtained for apo (0.7960.13) and holo-
FGF2 (0.7860.12) indicating that no global conformational
flexibility variation occurs upon sm27 binding. The highly flexible
Mechanism of Direct and Allosteric FGF2 Inhibition
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low S2 values for both the apo (S2=0.3360.15) and the holo-
FGF2 (0.3560.24). Likewise, the two C-terminal residues (K154
and S155) presented S2 values lower than 0.5, confirming the
considerable disordered nature of these two terminal regions on a
picosecond time scale regime. Interestingly, three residues of the
N-terminal tail (A11, G24, and F26) drastically reduced their
dynamic regime as a consequence of sm27 binding. In particular,
G24 and F26 reached S2 values higher than the average.
In apo-FGF2 six residues belonging to the protein core region,
namely V52 (b3 strand), E67 (b4 strand), C101 (b7–b8 loop), and
R129, K144, L147 (b10–b12 loop), showed a S2 #0.53
(corresponding to the average value minus two standard devia-
tions). Upon sm27 binding, motions of all these residues are
quenched (Figure 2E). On the other hand, upon sm27 binding,
five new residues, namely H59 (b3–b4 loop), N111 (b8–b9 turn),
R118 (b9–b10 loop), G142 (b10–b12 loop), and M151 (b12
strand), significantly decreased their S2 to values lower the
average.
R1rho relaxation parameters. R1rho experiments were
run to monitor the possibility that some residues might be affected
by slow conformational exchange phenomena in the microsecond-
Figure 1. Mapping of FGF2/sm27 interaction by NMR and docking simulations. A) Sm27 molecule: 4-hydroxy-6-[(8-hydroxy-6-
sulfonaphthalen-2-yl)carbamoylamino] naphthalene-2-sulfonic acid. B) Superimposed
1H-
15N HSQC spectra of free FGF2 (black), FGF2:sm27 in
stoichiometric ratios 1:1 (blue) and 1:2 (red). Spectral regions showing R129 and K144 behaviors are zoomed. C) Graphical representation of the
combined H
N and N FGF2 chemical shift perturbation determined for the various residues, according to [53] (Dd~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
DdHN ðÞ
2z
DdN
6
   2
s
), following
the addition of sm27 in 2:1 stoichiometric ratio. Gray and black bars refer to backbone and Asn, Gln and Arg side chain variations, respectively. D)
Bundle of the first 10 structures of cluster 1 obtained with HADDOCK. FGF2 in shown as a blue cartoon, sm27 is shown in yellow sticks. E) Summary of
the conserved protein-inhibitor interactions. K128, R129, Q143, and K144 side chains are shown as sticks and are labelled. H-bonds are depicted with
black dotted lines and atoms involved in hydrophobic interactions are showed as blurred spheres.
doi:10.1371/journal.pone.0036990.g001
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motions probed by measurements of R1. R2/R1rho ratio values
significantly deviating from one are indeed indicative of the
presence of conformational exchange. The values of the R2/
R1rho ratios, as a function of residue number, obtained for apo-
and holo-FGF2 are reported in Figure 2F, G. A number of
residues clearly showed ratios exceeding from one in both apo and
holo FGF2, namely, E3 and F26 (N-terminal tail), G51 (b3-strand),
L83 (b6-strand), E87 (b6–b7 loop), N110 (b8–b9 turn), G140 and
I146 (b10–b12 loop) (green spheres in Figure 2H). In the apo form
four additional residues were affected by conformational ex-
change: L64 (b4), Y124 (b10), R129 and K144 (b10–b12 loop)
(blue spheres in Figure 2H). Interestingly, upon sm27 binding, L64
and K144 R2/R1rho ratios clearly decreased and got closer to the
average, suggesting a quench of conformational exchange. Data
relative to residues Y124 and R129, although affected by larger
errors, are in the same line. On the other hand, increased
conformational exchange upon sm27 binding was observed in the
N-terminal (T7, T8, S18) and C-terminal (S152, A153) tails and at
the level of b6–b7 loop (G89) (red spheres in Figure 2H).
Mapping protein hydration by NMR. Water molecules at
protein surface are critical to their equilibrium structures and to
phenomena such as molecular recognition and protein–protein
interactions. NMR spectroscopy is a well suited technique to assess
the presence of bound waters through ePHOGSY experiments. In
this kind of spectra peak intensities depend on distance between
water and protein protons, on protein dynamics, and on the
residence time of water on the protein [24,25]. Assuming minor
exchange phenomena contribution, ePHOGSY correlations reveal
the presence of bound waters at protein sites [24]. Sizeable water-
protein Overhauser effects, possibly arising from intermolecular
contacts shorter than 4–5 A ˚ between the protein and resident
water molecules, were observed for apo and holo protein forms
(Figure S3 and S4) at the level of N terminal tail (E3, G24, H25
and F26), in the facing b8–b9 turn (N111) and at the level of
residues D46 (b2–b3 loop), A79 (b5–b6 loop), and K95 (b7–b8
loop) (Figure 3A).
Upon sm27 binding a significant increase in intensity of
ePHOGSY-NOE correlations occurred in the N-terminal tail
and at the level of sm27 binding sites. In particular, residues G17,
M85, E108, and K144 were affected (Figure 3B), with major effect
observed for K144 (Figure S3 and S4), reflecting an increased
residence time and/or a decreased distance of a water molecule
from its amide group upon binding. It should be mentioned that
G17 presented also a ROE correlation that however didn’t change
upon sm27 binding. The NOE variation of G17 thus indicated a
stabilization of the water molecule close to this residue. At
variance, for G19 and F21 a decrease of ROE and NOE effect
were observed, respectively.
Characterizing the internal dynamics of FGF2 through
MD simulations
The correlations between structure, dynamics and molecular
recognition mechanisms of FGF2 were in parallel investigated by
extensive molecular dynamics (MD) simulations on the apo form
of FGF2 and on the experimentally derived model of the FGF2/
sm27 complex.
From the structural point of view, FGF2 did not undergo any
significant conformational change during the course of the
simulations: the protein, in both the apo and bound states, visited
mainly native conformations, in agreement with NMR observa-
tions.
The presence of a specific ligand and its molecular properties,
on the other hand, may profoundly affect FGF2 internal dynamics
at both the local and global level, even in the absence of major
conformational changes.
These dynamic aspects could be characterized by analyzing, in
the course of the simulations, the fluctuations of the distances of all
pairs of aminoacids in FGF2 and the different patterns originating
from the absence/presence of sm27. This analysis, which has been
previously developed by some of us [26,27,28] was shown to yield
information on the existence of rigid/flexible regions in the
protein, as well as significant coordination in the dynamics of
Figure 2. Backbone dynamics of apo and holo FGF2 by NMR. A)
1H
15N-HSQC cross peaks normalized intensity (I) upon sm27 binding vs
residue number. Gray and black diamond refers to backbone amides, and glutamine, asparagine and arginine side chains, respectively. B)
1H
15N-
HSQC cross peaks intensity variations plotted on FGF2 molecule. Blue (filled) and red (dotted) spheres indicate residues showing an increased and
reduced intensity upon sm27 binding, respectively. The sphere radius is set according to the size of the variation. Side chains affected by intensity
variations are shown in sticks. R129 and K144 side chains are shown in yellow sticks for clarity reasons. C) Modelfree analysis order parameters (S2) for
the apo- and holo-FGF2 are reported in black and gray, respectively, as a function of the residue number. The black and gray straight lines represent
the S2 average value for the apo and holo FGF2, respectively. S2 values are mapped on FGF2 structure in D and E for the apo and holo form,
respectively. Color code: red for S2vS2{2s, where S2 and sare the average and the standard deviation for S2 values, respectively; orange for
S2{2sƒS2vS2{1s; white for S2{1sƒS2vS2; marine for S2ƒS2vS2z1s; blue for S2§S2z1s. Secondary structure elements are numbered
for clarity purposes. F) and G) R2/R1rhovalues as a function of the residue number are reported for the apo and holo FGF2, respectively. The
horizontal straight and dotted lines represent the average value and the average plus one standard deviation, respectively. H) Residues with R2/R1rho
exceeding from one in the apo and holo FGF2 are mapped on the protein structure. Green spheres represent residues affected by conformational
exchange in both the apo and holo form. Marine dotted spheres represent residues affected by conformational exchange only in the apo-FGF2 form.
Red spheres represent residues affected by conformational exchange upon sm27 binding. Residues with R2/R1rho values affected by significant
errors, either in the apo or in the holo form, are represented as dotted spheres.
doi:10.1371/journal.pone.0036990.g002
Figure 3. Water mapping by NMR. A) Hydration state of apo-FGF2:
residues showing NOE with water higher than the average are
represented as spheres with the sphere radius scaled according to
the proximity of a water molecule. Serines, threonines, and tyrosines
were excluded from the analysis because their peak intensity could be
partly due to relayed transfers via the exchanging OH groups of their
side-chains. Residues presenting ROE signals are excluded as well. B)
Residues affected by NOE and ROE e-PHOGSY intensity variations upon
sm27 binding are shown as spheres color coded in red and green,
respectively. Filled and dotted spheres indicate the increase and
decrease in peak intensity upon sm27 binding, respectively.
doi:10.1371/journal.pone.0036990.g003
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primary sequence.
The mean squared fluctuations (see Experimental Procedures)
of all pair wise distances in the apo and in the simulation of the
FGF2/sm27 complex are shown in Figure S5A, B. Due to its high
degree of disorder and flexibility, the N-terminal tail was excluded
from the analysis and the results refer to the region 25–155. The
matrices showed patterns reflecting the alternation of substructures
with small and large fluctuations of inter-residue distances. The
difference matrix, reporting on the variation of mean squared
fluctuations between apo and holo states, is shown in Figure 4A.
The presence of the ligand appeared to significantly affect the
degree of fluctuations of different groups of FGF2 aminoacids.
Specifically, the regions displaying quenched conformational
freedom upon binding (represented by gray to black shadings in
the matrix) correspond to part of the binding site region (residues
128–131) of b10–b12 loop, and to b4 strand and b4–b5 loop
(residues 66–71). Another striking feature of holo protein
simulation is the enhancement in the conformational freedom
(blue shading in Figure 4A) of residues 139–143 of the binding site,
and of residues 107 to 112, corresponding to the b8–b9 turn
region. This analysis is unable to catch the differences in the
motions observed for loops b3–b4, b7–b8 and b9–b10, identified
by NMR analysis. This inconsistency may be due to two main
causes: 1) insufficient or limited sampling of the MD-simulations,
which limits the conformational statistics that is used for the
analysis compared to the experimental situation. This may affect
particularly the evaluation of the motional properties of long and
flexible loops; 2) the fact that this specific analysis aims at
identifying coordinated motions between residue-pairs, while
NMR-based indicators mainly refer to single-residue motions. In
this framework, in order to analyze the mobility properties of
single residues in the context of a dynamic protein environment,
we calculated the time-dependent variation of the geometric
deformation (also named geometric strain, see [29]) experienced
by the various aminoacids in the course of the simulations.
Ligand-dependent modulation of strain. We set out to
calculate the distortions in the networks of contacts of each residue
during the simulations, in the presence or absence of the ligand
(see Methods). The parameter that recapitulates the difference
between the instantaneous and time-averaged distance of each
residue from its neighboring aminoacids is defined as geometric
strain. As a consequence, when carried out over the whole
trajectory, this quantity provides information on the changes in the
local geometry of 3D FGF2 architecture, and provides a compact
measure of the local flexibility properties of single residues in the
absence and in the presence of the inhibitor. This, in turn, allows
for pinpointing specific patterns of structural deformation that
emerge in the simulation evolution, providing a direct structural
mapping of ligand modulation, which can be qualitatively
correlated to NMR-based observations.
Figures 4B, C report the time-dependent geometric strain of
each amino acid for the apo and holo simulations analyzed. The
analysis showed that in the apo form the only significant strain-
related signal emerged in the region centered on residue 107 of b8
strand. In the presence of sm27, a systematic buildup/release of
the geometric strain involved specific protein regions, correspond-
ing to residues 34–37 (b1 and b1–b2 loop), 48–52 (b3 strand), 62–
67 (b4 strand), 72–74 (b5 strand), and 111–120 (b8–b9 loop, b9
strand, and b9–b10 loop). It is worth noting that the dynamic
perturbations of some of these regions were not captured by the
analysis of the mean square fluctuations, indicating a possible
different nature of the observed effects. Interestingly, consistent
changes in the local strain patterns are switched on for the binding
region involving residues 127–129, 134–136, and 138–142 of b10–
b12 loop.
Finally, the calculation of the average strain experienced by
each aminoacid (Figure S6) confirmed the presence of strain
hotspots that respond to ligand binding by increasing or
decreasing their local flexibility even if they are not in direct
contact with sm27. Strain hotspots correspond to the following
sequence stretches: 35–39 (b1–b2 loop and b2 strand), 54–57 (b3–
b4 loop), 63–67 (b4 strand), 69–72 (b4–b5 turn and b5 strand),
128–132 (b10–b12 loop), and 144 (b10–b12 loop).
Sm27 inhibition of the interaction of FGF2 with heparin/
HSPGs and FGFR1
The combined NMR and MD characterization of sm27 binding
to FGF2 revealed that the inhibitor targets a well defined region
extending over the FGF2 heparin-binding site. We thus exploited
SPR analysis to evaluate the ability of sm27 to bind FGF2 and
Figure 4. Internal dynamics of apo and holo FGF2. A) Difference
matrix obtained by subtracting the distance fluctuations of the apo
protein from those of the holo protein. B) Time evolution of the
geometrical strain for the apo FGF2; C. Time evolution of the
geometrical strain for the holo FGF2. The magnitude of the relative
fluctuations, expressed in A ˚2 units, is color coded according to the
legend on the right of each panel.
doi:10.1371/journal.pone.0036990.g004
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heparin, an experimental model that resembles the binding of
heparin binding growth factors to cell-associated HSPGs [30]. As
shown in Figure 5A, sm27 effectively prevents FGF2/heparin
interaction in a dose-dependent way with an IC50 equal to
3.5 mM, suggesting that the same inhibitory effect can be exerted
by sm27 also on the FGF2/HSPGs interaction at the cell surface.
As already described, analysis of the variations in the internal
dynamics of the apo- and holo-protein states suggested that sm27
perturbs, through a long-range mechanism, the FGFR1-binding
domain of the growth factor (vide infra), inferring possible
consequences also on the FGF2/FGFR1 interaction. To verify
this possibility, SPR was again exploited to evaluate the capacity of
sm27 to prevent the binding of FGF2 to substrate-immobilized
FGFR1. As shown in Figure 5A and S7, sm27 prevents FGF2/
FGFR1 interaction with a potency (ID50 equal to 4.0 mM) close to
that observed for the inhibition of the FGF2/heparin interaction.
Taken together, the above data indicate that sm27 interferes at the
same time with the interaction of FGF2 with both HSPGs and
FGFR1.
To confirm the interference of sm27 with FGF2 binding to both
HSPGs and FGFR1 in a cellular setting, binding of Eu-labelled
FGF2 was measured in wild-type CHO-K1 and in FGFR1-
transfected A745 CHO flg-1A cells. In these cells, FGF2 binding
was entirely mediated by HSPGs in wild-type CHO-K1 cells
(expressing HSPGs but not FGFR1) and by FGFR1 in A745 CHO
flg-1A cells (deficient in HSPGs and engineered to over-express
FGFR1), as confirmed by the inhibitory activity of heparin and
unlabelled FGF2 [31] in CHO-K1 and FGFR1-CHO, respec-
tively. In both cells types, FGF2 binding was inhibited by sm27
(Figure 5B), confirming the ability of the small molecule to affect
the interaction of FGF2 with both HSPGs and FGFR1. The
inhibitory effect of sm27 on FGF2-binding to FGFR1 and HSPGs
was confirmed on the more physiological system of endothelial
cells, naturally expressing both the classes of receptors. It was
possible to discriminate between FGF2 bound to HSPGs low
affinity receptors and FGF2 bound to the high affinity FGFR1,
following a previously reported procedure [31]. Sm27 inhibited
FGF2 binding to both classes of receptors also in this cell system
(Figure 5C). In these assays, higher concentrations of sm27 were
required to achieve inhibition, possibly because of the higher
degree of molecular complexity implied in cell systems, both in
terms of variety and concentration of the competing receptors and
their interacting ligands.
To exert its pro-angiogenic activity, FGF2 needs to set up a
productive, ternary complex with HSPGs and FGFR1 [32]. To
investigate whether sm27 was able to prevent the formation of
such a complex, a cell-cell adhesion model was used in which
FGF2 mediates the interaction of FGFR1
+/HSPG
2 A745 CHO
flg-1A cells to a monolayer of FGFR1
2/HSPG
+ CHO-K1 cells
[33]. As shown in Figure 5D, sm27 inhibited FGF2-mediated cell-
cell adhesion (ID50 equal to 1 mM), thus indicating its capacity to
prevent the formation of the FGF2/FGFR1/HSPGs complex.
Taken together, all these data are in agreement with our previous
observation that sm27 inhibits the mitogenic activity exerted by
FGF2 on endothelial cells in vitro and FGF2-dependent angiogen-
esis in vivo [9].
Discussion
The current view of protein structural biology focuses on the
fundamental role of dynamic conformational ensembles in
molecular recognition [34]. Although there is a large consensus
on the role of internal motions in determining function, the
understanding, at atomic resolution, of their relationships and
relevance in the design/discovery field is more difficult [35,36].
In this paper, we have used NMR and MD simulations studies
to shed light on the variations in the internal motions of FGF2
determined by the binding of the inhibitor sm27, and to propose a
direct and allosteric mechanism of inhibition. It was then of pivotal
importance the possibility to test this hypothesis through SPR, a
cell-free technology that allows the study of macromolecular
interactions in well defined conditions, and through more
physiological systems represented by binding assays on cultured
cells.
NMR and data driven docking analysis clearly indicated that
sm27 engages the heparin-binding site of FGF2, making hydro-
phobic and hydrophilic contacts with residues K128, R129, Q143
and K144. In particular NMR experimental data (CSP and NOE)
suggested that residues R129 and K144 are the two hotspots of this
interaction. Strong similarities with the inhibitor binding site
recently reported for FGF1 [37] are observed. Indeed, the
structures of FGF1 in complex with effective inhibitors of
angiogenesis (gentisic acid and derivatives, PDB id: 3JUT,
3K1X) identified in the FGF1-corresponding residues (namely
K127 and K142) the anchoring points of the inhibitor [37]. The
Figure 5. Effect of sm27 on the interaction of FGF2 with
heparin/HSPGs and FGFR1. A) FGF2 (150 nM) was injected over
heparin or FGFR1 immobilized to a SPR sensorchip in the absence or in
the presence of increasing concentrations of sm27 and the amount of
FGF2 bound to the surfaces in the different experimental conditions
was then measured. Each point is the mean 6 SEM of 3 separate
experiments. B) Binding of Eu-FGF2 to CHO cells expressing either
HSPGs or FGFR1 in the presence of sm27. C) Binding of Eu-FGF2 to
endothelial cells (BAEC). D) Effect of sm27 on the formation of the
HSPGs/FGF2/FGFR1 complex. FGFR1
+/HSPG
2 A745 CHO flg-1A cells
were added to a monolayer of FGFR1
2/HSPG
+ CHO-K1 cells in serum-
free medium with FGF2 (1.66 nM) in the presence of increasing
concentrations of sm27. After 2 h of incubation at 298K, the cells bound
to the monolayer were counted under an inverted microscope. Each
point is the mean 6 SEM of 3 separate experiments performed in
triplicate. In B and C, black and white arrows indicate the inhibitions
obtained with heparin (0.1 mg/ml) and unlabeled FGF2 (1.5 mg/ml) used
as reference competitor of HSPGs and FGFR1 binding, respectively
doi:10.1371/journal.pone.0036990.g005
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by SPR analysis as well as in cell based binding assays, which
demonstrated that sm27 is able to effectively interfere with
heparin/FGF2 interaction. In this respect sm27, originally
designed to mimic the binding and physiological activity of TSP-
1, maintained the properties of TSP-1 and its FGF2-binding
sequence [6,7,8,9].
Direct interference of sm27 with HSPGs recognition of FGF2 is
however only one side of sm27 inhibitory mechanism. Indeed
dynamics analysis of the apo and holo FGF2 states performed by
NMR and MD, which allows the characterization of motion
changes in a timescale range from picosecond to milliseconds,
showed that the effects of sm27 binding extended far beyond the
interaction site. Figure 6 provides the structural representation of
residues affected by dynamical changes upon binding, as deduced
by data analysis. Three protein regions could be identified
involving residues: i) close to the binding site; ii) distal from the
binding site; iii) belonging to N and C-terminal tails. NMR
hydration studies detected as well changes of hydration pattern at
the level of the binding site and in the flexible N-terminal region
upon binding (Figure 3B). Overall, the combined results from
NMR and MD investigations revealed common perturbation
patterns that impact on functionally relevant regions of FGF2 in
response to ligand binding. As shown in the results, the employed
MD-derived parameters show variable levels of agreement with
NMR-derived data. Specifically, coordination analysis of residue
pairs, based on the calculation of mean-square fluctuations,
catches motional variations that involve set of residues in part
different from the ones revealed by strain analysis. On this basis,
we speculate that the observed differences may arise from distinct
perturbation mechanisms. The coordination analysis may indicate
sets of residues that respond in a cooperative, concerted manner to
the presence of the ligand in the binding site. The aminoacids that
are highlighted by the strain analysis, on the other hand, may
indicate protein regions that respond by simply changing their
contacts with the perturbed local environment. At this stage,
however, this discussion must be considered as a qualitative one,
and further and more quantitative coordination analysis of MD
simulations are required [38].
In many biological systems proteins respond to ligand binding
by redistributing their internal dynamics [39,40,41,42,43], which
in turn mediate long-range communication. Proteins exist in a
number of different substates around their native states, and their
relative populations can change following perturbative events,
such as ligand binding. In this framework, allostery represents a
phenomenon in which a binding event at a certain site perturbs
the dynamics of the conformational ensemble, possibly changing
the recognition properties at a second site.
In this respect it is worth mentioning that the observed long
range effects, detected upon inhibitor binding, affect protein
regions directly involved in the tyrosine kinase receptor recogni-
tion. Specifically, the perturbed FGF2 regions face the D2, D3
domains and D2-D3 linker of FGFR1[16] (Figure 6). In the same
line dynamics variations were observed for FGF1, in the region
interacting with the cellular receptor, upon binding of a
hexasaccaride heparin-analogue [44].
The functional consequences of the inhibitor induced dynamic
perturbation of FGF2 regions involved in receptor binding, could
be clearly detected by SPR methods suggesting an impaired
FGF2/FGFR1 interaction. Moreover sm27 was able to inhibit
FGF2 binding to FGFR1 in two cell systems, the CHO cells,
lacking HSPG but expressing FGFR1, and endothelial cells
naturally expressing both classes of receptors. The observed
perturbations of FGF2/FGFR1 recognition properties thus clearly
reported on an allosteric event.
The double action of sm27–direct inhibition of FGF2 binding to
heparin and allosteric inhibition of FGF2 binding to FGFR1–has
potential profound effects on the activity of the growth factor. The
binding of FGF2 to HSPGs is indeed required to set up a
productive FGF2/HSPGs/FGFR1 ternary complex that, in turn,
allows for FGF2 pro-angiogenic activity [45]. Although other
FGF2-antagonist have been described that inhibit the formation of
the ternary complex, they always act by specifically interfering
with the interaction of the growth factor with either HSPGs [45]
or FGFR1 [46], leaving unaffected the other interaction. In this
scenario, sm27 represents the first fully characterized example of
an FGF2-antagonist that acts by a twofold mechanism of action,
i.e. by interfering simultaneously with the two growth factor
interactions required for its pro-angiogenic activity.
Because of this unique mechanism of action, sm27 can be
considered the prototype of a new class of FGF2-inhibitors. At this
stage, we cannot exclude that previously discovered molecules
FGF2-directed drugs may also be allosteric modulators, since
analyses similar to the ones presented here were not applied. In the
context of our investigations, ongoing studies on a set of second
generation, sm27-related molecules, will investigate whether it is
possible to exploit dynamical information in the design of
inhibitors with increased affinity for FGF2 and potentiated
inhibition of FGF2/receptor binding and antiangiogenic activity.
Assuming that specific interactions underlie the transmission of
allosteric mechanisms, a series of sm27-related compounds, in
which the original scaffold is decorated with groups that contact
residues near the binding site whose dynamic properties have been
shown to change, will be tested. MD and NMR evaluation of the
long-range effects of such modifications, based on the analysis of
perturbed regions and of dynamic coordination pathways, will
allow to select profitable allosteric inhibitors. Small molecules
causing the same type of long-range perturbation of FGF2
dynamics as observed for sm27 will be selected for further in
vitro and cellular analyses of their effects on receptor recognition.
Materials and Methods
Chemicals
Sm27 (NSC37204) was from NCI, National Institutes of Health
(Rockville, MD). Human recombinant FGF2 was produced and
purified as described in Supporting Information S1.
FGF2/sm27 interactions assessed by NMR
NMR spectra were collected on samples containing 0.57 mM
15N-labeled FGF2, dissolved in 50 mM potassium phosphate
buffer pH 5.5 (90% H2O/10% D2O), 2 mM NaN3,1 0 m M
deuterated DTT, in the presence of variable concentrations of
sm27 (in the range 0 to 2 mM). All NMR data were collected on a
Bruker DMX 500 MHz spectrometer at 298 K.
Model of the FGF2/sm27 complex
Models of the FGF2/sm27 complex were generated with the
data driven docking simulations software HADDOCK2.0 [22]
using AIR deduced from CSP data. NOE intermolecular contacts
were converted into distances and used as unambiguous restraints.
RMSD values of ensemble from their mean structure was
calculated with PROFIT (Martin, A. C. R., http://www.bioninf.
org.uk/software/profit).
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HSQC-based experiments were recorded to measure
15N
longitudinal T1 and transverse T2 relaxation rates, heteronuclear
1HR
15N NOE experiments and
15N rotating frame relaxation
rates T1rho. Relaxation parameters were analyzed with the
program Modelfree 4.20 [23]. The relaxation data were analyzed
with both isotropic and axially symmetric model and the latter
model was selected. Backbone relaxation data were fit to the five
standard Lipari–Szabo model-free formalism models [23].
NMR Hydration studies
2D ePHOGSY-HSQC experiments with NOE and ROE steps
were recorded in order to discriminate between Overhauser and
exchange effects. The pulse used for selective water excitation was
a 50 ms long 180u Gaussian pulse. The mixing and spin-lock
periods for NOE and ROE steps, respectively, were 80 ms long.
Molecular Dynamics studies of the apo FGF2 and FGF2/
sm27 complex
The Apo structure of FGF-2 and the structure of the complex
obtained as described above were each subjected to MD
simulation analysis to a 100 ns long Molecular Dynamics (MD)
simulation in explicit water.
All MD simulations were performed using the AMBER 9.0
package [47] with the ff03 force field, the TIP3P water model [48],
and the Particle Mesh Ewald summation method (PME) to deal
with long-range Coulomb interactions [49].
Surface plasmon resonance (SPR) analysis
SPR measurements were performed on a BIAcore X instrument
(GE-Healthcare, WI). Heparin was immobilized onto the SPR chip
asdescribed[30],allowingtheimmobilizationof80resonanceunits
(RU) (6.0 fmol/mm
2). Immobilization of FGFR (13,800 RU,
42.0 fmol/mm
2), is described in the Supporting Information S1.
Sensorchips coated with streptavidin or FGF-unrelated noggin
proteinwereusedforblanksubtraction(respectivelyforheparinand
FGFR-1).Forcompetitionexperiments,FGF2wasinjectedoverthe
heparin or FGFR1 surfaces for 5 min in the presence of sm27 and
washed until dissociation was observed.
Cell cultures
Wild-type CHO-K1 cells not expressing FGFR1 and the
derived HSPG-deficient A745 CHO cell mutants [50] were kindly
provided by J. D. Esko (La Jolla, CA). FGFR1-transfected A745
CHO were generated as described in [51]. Cells were grown in
Ham’s F-12 with 10% FCS. Bovine aortic endothelial cells (BAEC)
[52], provided by E. Dejana (Milano, Italy) were cultured in
DMEM with 10% FCS.
Binding of FGF2 to cells
Binding of Europium-labeled FGF2 (Eu-FGF2, 10 ng/ml) to
BAEC, CHO-K1 and FGFR1-expressing A745 CHO cells was
measured in the presence of sm27, heparin or unlabeled FGF2,
essentially as described [9]. Binding to low and high affinity
receptors was analyzed according to [31].
FGF2-mediated cell-cell adhesion assay
FGF-2-dependent binding of A745 CHO flg-1A cells to a
monolayer of fixed, wild-type CHO-K1 cells was measured in the
presence of increasing concentrations of sm27, as described [33].
Data are mean bound cells in three random microscopic fields.
Full details of all the procedures are given in the Supporting
Information S1.
Supporting Information
Figure S1
1H and
15N chemical shift perturbation
analysis. Separate
1H and
15N analysis of chemical shift
perturbation in 2:1 sm27:FGF2 sample.
(DOC)
Figure S2 NMR relaxation parameters (R1, R2 and
1H-
15N NOE). R1, R2 and
1H-
15N NOE values measured for
Figure 6. Summary of change in FGF2 dynamics upon sm27 binding. The representative structure of FGF2-sm27 complex is shown in grey.
Dynamics variations are mapped on the FGF2 structure. Blu and red colors code for decreased and increased backbone motions upon inhibitor
binding. A) NMR data: colored ribbon represents S2 variations, sticks describe slow conformational exchange variations (R1rho) and spheres indicate
residues affected by HSQC intensity changes upon sm27 binding. B) MD data: mean squared fluctuations differences of all pair wise distances
between the apo and holo form. For clarity purposes the complex was superimposed to the X-ray structure of FGFR1-FGF1 dimer (PDB id: 1FQ9) and
the FGFR1 regions making contacts with FGF2 are shown. The two FGFR1 units are shown as green and light green cartoons.
doi:10.1371/journal.pone.0036990.g006
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and 298K are plotted as a function of residue number.
(DOC)
Figure S3 ePHOGSY spectra of apo and holo forms.
1H-
15N
ePHOGSY HSQC spectra with NOE step for the apo-(A) and holo-
FGF2 (B), and with ROE step for the apo (C) and holo-FGF2 (D). In A
and B, negative peaks are colored in red. In B and D insets, peaks are
colored black and blue for the apo and holo forms, respectively.
(DOC)
Figure S4 Comparison of ePHOGSY cross peak intensities
of apo and holo forms. ePHOGSY NOE (gray) and ROE (blue)
normalized intensities are shown as a function of the residue number in
A and B for the apo and holo FGF2, respectively. Straight and dotted
lines correspond to the thresholds employed to classify the residues in
three groups on the basis of the entity of the observed ePHOGSY
effects. In C, the ratio of the normalized intensities observed for holo
and apo FGF2 is reported as a function of the residue number for
ePHOGSY NOE (gray) and ROE (blue) correlations. Dotted lines
delimit intensity variations beyond 6 50% upon sm27 binding.
Residues showing significant variations are labeled.
(DOC)
Figure S5 Distance fluctuation matrices for apo and
holo FGF2. Mean squared fluctuations of all pair wise distances in
the apo (A) and in the simulation of the FGF2/sm27 complex (B) The
magnitude of pairwise distance fluctuations, expressed in A ˚ 2 units, is
color coded from blue (small fluctuations)to white (large fluctuations).
(DOC)
Figure S6 Average strain profile. The residue based profile
of average strain calculated over the simulation time for the apo
(black line) and for the holo (red line) FGF2.
(DOC)
Figure S7 SPR analysis of the effect of sm27 on FGF2
interaction with FGFR1 and heparin. Blank-subtracted
sensorgrams showing the binding of FGF2 (150 nM) in the
absence (straight lanes) or in the presence (dashed lines) of sm27
(5 nM) to a BIAcore sensorchip coated with heparin (upper panel)
or FGFR1 (lower panel). The response (in resonance units, RU)
was recorded as a function of time.
(DOC)
Table S1 Summary of unambiguous and ambiguous
interaction restraints employed for HADDOCK calcula-
tions.
(DOC)
Table S2
1H chemical shift of sm27 molecule at pH 5.5,
298K.
(DOC)
Table S3 Statistics of the top three FGF2-sm27 clusters obtained
with HADDOCK.
(DOC)
Table S4 Average NMR relaxation parameters values of apo-
and holo-FGF2 calculated over the residue range 30–152.
(DOC)
Information S1 Full details of the experimental proce-
dures.
(DOC)
Author Contributions
Conceived and designed the experiments: KP LZ MP MR GT GC LR.
Performed the experiments: KP RT CF AB ST. Analyzed the data: KP
MR GT GC LR. Wrote the paper: KP MR GT GC LR.
References
1. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development
to cancer. Nat Rev Cancer 10: 116–129.
2. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology
and therapy. Nat Rev Drug Discov 8: 235–253.
3. Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their
receptors in cancer. Biochemical Journal 437: 199–213.
4. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, et al. (1990) A
tumor suppressor-dependent inhibitor of angiogenesis is immunologically and
functionally indistinguishable from a fragment of thrombospondin. Proc Natl
Acad Sci U S A 87: 6624–6628.
5. Taraboletti G, Roberts D, Liotta LA, Giavazzi R (1990) Platelet thrombos-
pondin modulates endothelial cell adhesion, motility, and growth: a potential
angiogenesis regulatory factor. J Cell Biol 111: 765–772.
6. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, et al. (2003)
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor
2. Blood 102: 4399–4406.
7. Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, et al. (1997) The
140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic
fibroblast growth factor. Cell Growth Differ 8: 471–479.
8. Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, et al. (2008)
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a
novel antiangiogenic domain. Int J Biochem Cell Biol 40: 700–709.
9. Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, et al. (2010) Non-
peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an
integrated strategy for the development of new antiangiogenic compounds. J Biol
Chem 285: 8733–8742.
10. Fernandez-Tornero C, Lozano RM, Redondo-Horcajo M, Gomez AM,
Lopez JC, et al. (2003) Leads for development of new naphthalenesulfonate
derivatives with enhanced antiangiogenic activity: crystal structure of acidic
fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. J Biol
Chem 278: 21774–21781.
11. Taraboletti G, Rusnati M, Ragona L, Colombo G (2010) Targeting tumor
angiogenesis with TSP-1-based compounds: rational design of antiangiogenic
mimetics of endogenous inhibitors. Oncotarget 1: 662–673.
12. Heath WF, Cantrell AS, Mayne NG, Jaskunas SR (1991) Mutations in the
heparin-binding domains of human basic fibroblast growth factor alter its
biological activity. Biochemistry 30: 5608–5615.
13. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, et al. (2004)
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests
distinct pathophysiological mechanisms for craniofacial and limb abnormalities.
Hum Mol Genet 13: 2313–2324.
14. Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mohammadi M (2004)
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and
Muenke craniosynostosis syndromes through enhancement of FGF binding
affinity. Hum Mol Genet 13: 69–78.
15. Li LY, Safran M, Aviezer D, Bohlen P, Seddon AP, et al. (1994) Diminished
heparin binding of a basic fibroblast growth factor mutant is associated with
reduced receptor binding, mitogenesis, plasminogen activator induction, and in
vitro angiogenesis. Biochemistry 33: 10999–11007.
16. Mohammadi M, Olsen SK, Ibrahimi OA (2005) Structural basis for fibroblast
growth factor receptor activation. Cytokine Growth Factor Rev 16: 107–137.
17. Seno M, Sasada R, Kurokawa T, Igarashi K (1990) Carboxyl-terminal structure
of basic fibroblast growth factor significantly contributes to its affinity for
heparin. Eur J Biochem 188: 239–245.
18. Moy FJ, Seddon AP, Bohlen P, Powers R (1996) High-resolution solution
structure of basic fibroblast growth factor determined by multidimensional
heteronuclear magnetic resonance spectroscopy. Biochemistry 35:
13552–13561.
19. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, et al. (1995) FGF
binding and FGF receptor activation by synthetic heparan-derived di- and
trisaccharides. Science 268: 432–436.
20. Krishnamoorthy J, Yu VC, Mok YK (2010) Auto-FACE: an NMR based
binding site mapping program for fast chemical exchange protein-ligand
systems. PLoS One 5: e8943.
21. de Vries SJ, van Dijk AD, Krzeminski M, van Dijk M, Thureau A, et al. (2007)
HADDOCK versus HADDOCK: new features and performance of HAD-
DOCK2.0 on the CAPRI targets. Proteins 69: 726–733.
22. Dominguez C, Boelens R, Bonvin AM (2003) HADDOCK: a protein-protein
docking approach based on biochemical or biophysical information. J Am Chem
Soc 125: 1731–1737.
23. Mandel AM, Akke M, Palmer AG 3rd (1995) Backbone dynamics of Escherichia
coli ribonuclease HI: correlations with structure and function in an active
enzyme. J Mol Biol 246: 144–163.
Mechanism of Direct and Allosteric FGF2 Inhibition
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e3699024. Niccolai N, Spadaccini R, Scarselli M, Bernini A, Crescenzi O, et al. (2001)
Probing the surface of a sweet protein: NMR study of MNEI with a
paramagnetic probe. Protein Sci 10: 1498–1507.
25. Otting G (1997) NMR studies of water bound to biological molecules. Progress
in Nuclear Magnetic Resonance Spectroscopy 31: 259–285.
26. Morra G, Neves MAC, Plescia CJ, Tsustsumi S, Neckers L, et al. (2010)
Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for
the C-terminal Domain of Hsp90. Journal of Chemical Theory and
Computation 6: 2978–2989.
27. Morra G, Verkhivker G, Colombo G (2009) Modeling signal propagation
mechanisms and ligand-based conformational dynamics of the Hsp90 molecular
chaperone full-length dimer. PLoS Comput Biol 5: e1000323.
28. Torella R, Moroni E, Caselle M, Morra G, Colombo G (2010) Investigating
dynamic and energetic determinants of protein nucleic acid recognition: analysis
of the zinc finger zif268-DNA complexes. BMC Struct Biol 10: 42.
29. Pontiggia F, Zen A, Micheletti C (2008) Small- and large-scale conformational
changes of adenylate kinase: a molecular dynamics study of the subdomain
motion and mechanics. Biophys J 95: 5901–5912.
30. Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, et al. (2001)
Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem
276: 22420–22425.
31. Moscatelli D (1988) Metabolism of receptor-bound and matrix-bound basic
fibroblast growth factor by bovine capillary endothelial cells. J Cell Biol 107:
753–759.
32. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, et al.
(2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual
role for heparin in FGFR binding and dimerization. Mol Cell 6: 743–750.
33. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, et al. (2001) Fibroblast
growth factor-2 antagonist activity and angiostatic capacity of sulfated
Escherichia coli K5 polysaccharide derivatives. J Biol Chem 276: 37900–37908.
34. Kar G, Keskin O, Gursoy A, Nussinov R (2010) Allostery and population shift in
drug discovery. Current Opinion in Pharmacology 10: 715–722.
35. Mauldin RV, Carroll MJ, Lee AL (2009) Dynamic dysfunction in dihydrofolate
reductase results from antifolate drug binding: modulation of dynamics within a
structural state. Structure 17: 386–394.
36. Peng JW (2009) Communication Breakdown: Protein Dynamics and Drug
Design. Structure (London, England: 1993) 17: 319–320.
37. Fernandez IS, Cuevas P, Angulo J, Lopez-Navajas P, Canales-Mayordomo A,
et al. (2010) Gentisic acid, a compound associated with plant defense and a
metabolite of aspirin, heads a new class of in vivo fibroblast growth factor
inhibitors. J Biol Chem 285: 11714–11729.
38. Morra G, Potestio R, Micheletti C, Colombo G (2012) Corresponding
Functional Dynamics across the Hsp90 Chaperone Family: Insights from a
Multiscale Analysis of MD Simulations. PLoS Comput Biol 8(3): e1002433.
39. Bouguet-Bonnet S, Buck M (2008) Compensatory and long-range changes in
picosecond-nanosecond main-chain dynamics upon complex formation: 15N
relaxation analysis of the free and bound states of the ubiquitin-like domain of
human plexin-B1 and the small GTPase Rac1. J Mol Biol 377: 1474–1487.
40. Das R, Chowdhury S, Mazhab-Jafari MT, Sildas S, Selvaratnam R, et al. (2009)
Dynamically driven ligand selectivity in cyclic nucleotide binding domains. J Biol
Chem 284: 23682–23696.
41. Das R, Mazhab-Jafari MT, Chowdhury S, SilDas S, Selvaratnam R, et al.
(2008) Entropy-driven cAMP-dependent allosteric control of inhibitory interac-
tions in exchange proteins directly activated by cAMP. J Biol Chem 283:
19691–19703.
42. Ravindranathan S, Oberstrass FC, Allain FH (2008) Increase in backbone
mobility of the VTS1p-SAM domain on binding to SRE-RNA. J Mol Biol 396:
732–746.
43. Tzeng SR, Kalodimos CG (2011) Protein dynamics and allostery: an NMR
view. Curr Opin Struct Biol 21: 62–67.
44. Canales-Mayordomo A, Fayos R, Angulo J, Ojeda R, Martin-Pastor M, et al.
(2006) Backbone dynamics of a biologically active human FGF-1 monomer,
complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation
methods. J Biomol NMR 35: 225–239.
45. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, et al. (2005)
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molec-
ular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast
growth factor antagonists. Arterioscler Thromb Vasc Biol 25: 71–76.
46. Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, et al. (2010) Fibroblast growth
factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic
pentapeptide. J Cell Mol Med 14: 2109–2121.
47. Case DA, Darden TA, Cheatham TEI, Simmerling CL, Wang J, et al. (2006)
AMBER 9. University of California, San Francisco.
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983)
Comparison of simple potential functions for simulating liquid water. J Chem
Phys 79: 926–935.
49. Darden T, York D, Pedersen L (1993) Particle Mesh Ewald-an N. Log(N)
method for Ewald sums in large systems. J Chem Phys 98: 10089–10092.
50. Esko JD (1991) Genetic analysis of proteoglycan structure, function and
metabolism. Curr Opin Cell Biol 3: 805–816.
51. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, et al. (1999) Modulation of
fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by
heparin-mimicking polysulfonated compounds. Mol Pharmacol 56: 204–213.
52. Taraboletti G, Belotti D, Dejana E, Mantovani A, Giavazzi R (1993)
Endothelial cell migration and invasiveness are induced by a soluble factor
produced by murine endothelioma cells transformed by polyoma virus middle T
oncogene. Cancer Res 53: 3812–3816.
53. Mulder FA, Schipper D, Bott R, Boelens R (1999) Altered flexibility in the
substrate-binding site of related native and engineered high-alkaline Bacillus
subtilisins. J Mol Biol 292: 111–123.
Mechanism of Direct and Allosteric FGF2 Inhibition
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36990